Unexpected finding points to potential way to stop macular degeneration
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight. The finding may allow doctors to halt the inflammation early on, potentially saving patients from blindness.
“Almost 200 million people in the world have macular degeneration. If macular degeneration were a country, it would be the eighth most populated nation in the world. That’s how large a problem this is,” said Jayakrishna Ambati, MD, vice chairman for research of UVA’s Department of Ophthalmology and the founding director of UVA’s Center for Advanced Vision Science. “For the first time, we know in macular degeneration what is one of the very first events that triggers the system to get alarmed and start, to use an anthropomorphic term, hyperventilating. This overdrive of inflammation is what ultimately damages cells, and so, potentially, we have a way of interfering very early in the process.”
Potential New Treatment for Macular Degeneration
Ambati and Nagaraj Kerur, PhD, assistant professor in the Department of Ophthalmology, and their laboratories have determined that the culprit is an enzyme called cGAS. The enzyme plays an important role in the body’s immune response to infections by detecting foreign DNA. But the molecule’s newly identified role in the “dry” form of age-related macular degeneration comes as wholly unexpected.
“It’s really surprising that in macular degeneration, which, as far as we know, has nothing to do with viruses or bacteria, that cGAS is activated, and that this alarm system is turned on,” Ambati said. “This is what leads to the killing of the cells in the retina, and, ultimately, vision loss.”
The researchers noted that cGAS may be an alarm not just for pathogens but for other harmful problems that warrant responses from the immune system. The enzyme may also play important roles in conditions such as diabetes, lupus and obesity, and researchers already are working to create drugs that could inhibit its function. “Because the target we’re talking about is an enzyme, we could develop small molecules that could block it,” Kerur said. “There are many drugs already on the market that target specific enzymes, such as the statins [which are used to lower cholesterol levels.]”
The promising new lead comes as good news for researchers seeking to develop new treatments for dry macular degeneration, as clinical trials in recent years have come to dead end after dead end.
The UVA researchers expect the development of a drug to inhibit cGAS will take several years, and that drug would then need to go through extensive testing to determine its safety and effectiveness for combating macular degeneration.
The researchers also hope to develop a way to detect the levels of the enzyme in patients’ eyes. That would let them determine when best to administer a treatment that blocks cGAS. “If they have high levels of this enzyme in their eye, they might be a wonderful candidate for this sort of treatment,” Ambati said. “This is really precision medicine at the single-molecule level.”
The Latest on: Macular degeneration
- Effects of Lutein Supplementation in Japanese Patients with Unilateral Age-Related Macular Degeneration: The Sakai Lutein Studyon April 6, 2020 at 2:10 am
This prospective randomized double-masked study investigated the effects of 20 mg lutein supplementation with two different capsules (beeswax or glycerol fatty acid esters) for 6 months on the fellow ...
- Iveric bio's Zimura Fast Track'd for macular degenerationon April 3, 2020 at 10:24 am
The FDA has granted Fast Track designation to's (NASDAQ:ISEE) Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA ...
- ‘It just ravaged his lungs’: Conway, SC, family shares details of coronavirus deathon April 3, 2020 at 7:59 am
He was in respiratory distress, he was sweating profusely. I could just look at him and I knew it was serious.” ...
- OCT-A characterisation of recurrent type 3 macular neovascularisationon March 30, 2020 at 10:01 am
Methods In this retrospective cohort study, consecutive patients with type 3 MNV secondary to age-related macular degeneration underwent OCT-A at three different time points: baseline, after ...
- Juvenile Macular Degeneration (Stargardt Disease) Pipeline Review, H1 2020 - ResearchAndMarkets.comon March 27, 2020 at 4:39 am
Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This pipeline guide Juvenile Macular Degeneration (Stargardt Disease) Pipeline Review, H1 2020, provides ...
- A tooth-enamel protein is found in eyes with a common form of macular degenerationon March 23, 2020 at 5:05 am
Deposits of a mineral found in tooth enamel at the back of the eye could be hastening the progression of age-related macular degeneration, the leading cause of deteriorating eyesight in people over 50 ...
- Iveric bio the latest to be hit by COVID-19 as it delays a key trialon March 18, 2020 at 6:22 am
secondary to dry age-related macular degeneration (AMD). The New York-based biotech said this was “for the safety and well-being of our elderly patients and participating physicians and their ...
- RIBOMIC Enters License Agreement with AJU Pharma for RBM-007 in Age-related Macular Degenerationon March 17, 2020 at 5:05 pm
RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company for RBM-007 licensing agreement.
- BRIEF-Ribomic Enters License Agreement With Aju Pharma For Rbm-007 In Age-Related Macular Degenerationon March 17, 2020 at 3:34 pm
Ribomic Inc: * RIBOMIC ENTERS LICENSE AGREEMENT WITH AJU PHARMA FOR RBM-007 IN AGE-RELATED MACULAR DEGENERATION * RIBOMIC - UPON EXECUTION OF AGREEMENT, AJU W ...
- Vitamin Science Announces VisiVite Sugar-Free Chewable AREDS 2 Vitamins for Macular Degenerationon March 11, 2020 at 4:42 am
Vitamin Science, Inc., manufacturer of premium ocular supplements since 2001, today announced a unique, ground-breaking chewable AREDS 2 eye vitamin supplement for people with age-related macular ...
via Google News and Bing News